Skip to main content
    E

    Envoy Medical Inc. (COCH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.92
    +0.18 (+2.75%)

    Market Cap: $52.16M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Envoy Medical Inc. (COCH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Envoy Medical (COCH) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Envoy Medical reported EPS of -$0.50, above the -$0.70 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(4/12)
    Avg Surprise
    -16.36%
    Streak
    4 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.71
    Range-$0.88 - -$0.63
    5 analysts
    Revenue Consensus
    $88.40K
    Range$58.80K - $105.00K
    5 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.61
    Range-$0.66 - -$0.53
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.65+6.2%
    60d ago-$0.65+6.2%
    30d ago-$0.63+3.7%
    7d ago-$0.65+5.7%
    Current-$0.61
    Revenue Consensus
    $100.00K
    Range$100.00K - $100.00K
    3 analysts

    Next Report

    COCH has an expected report date of Mar 22, 2027.

    COCH Earnings Call

    The latest COCH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 12 quarters below that had an estimate, COCH beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $66000, up 57.1% from $42000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.50-$0.70-$0.70 - -$0.62+28.57%BeatN/A30 up, 1 downNov 5, 2026$66000
    Jun 30, 2026-$0.07-$0.09-$0.09 - -$0.07+22.22%BeatN/A20 up, 1 downAug 10, 2026$51000
    Mar 31, 2026-$0.08-$0.14-$0.14 - -$0.14+42.86%BeatN/A10 up, 0 downMay 11, 2026$39000
    Dec 31, 2025-$2.67-$2.90-$2.90 - -$2.90+7.80%BeatN/A11 up, 0 downMar 23, 2026$75000
    Sep 30, 2025-$0.35-$0.29-$0.32 - -$0.24-20.69%MissN/A31 up, 0 downNov 10, 2025$42000
    Jun 30, 2025-$0.32-$0.29-$0.30 - -$0.28-10.34%MissN/A32 up, 0 downJul 31, 2025$78000
    Mar 31, 2025-$0.29-$0.20N/A-45.00%MissN/A41 up, 2 downMay 1, 2025$46000
    Dec 31, 2024-$0.46-$0.31-$0.39 - -$0.24-48.39%MissN/A30 up, 0 downMar 28, 2025$42000
    Sep 30, 2024-$0.37-$0.27-$0.31 - -$0.24-37.04%Miss-395.5%30 up, 0 downNov 14, 2024$56000
    Jun 30, 2024-$0.27-$0.25-$0.26 - -$0.24-8.00%MissN/A40 up, 0 downAug 12, 2024$68000
    Mar 31, 2024-$0.32-$0.26N/A-23.08%MissN/A30 up, 0 downMay 15, 2024$59000
    Dec 31, 2023-$0.39-$0.19-$0.20 - -$0.19-105.26%MissN/A20 up, 0 downMar 29, 2024$95000
    Sep 30, 2023$0.13N/AN/AN/AN/A+13.8%N/AN/ANov 17, 2023$80000
    Jun 30, 2023-$0.76N/AN/AN/AN/A-1370.0%N/AN/AAug 30, 2023$63000
    Mar 31, 2023-$0.04N/AN/AN/AN/A-117.4%N/AN/AMay 15, 2023$78000
    Dec 31, 2022-$0.38N/AN/AN/AN/AN/AN/AN/ADec 31, 2022$180000
    Sep 30, 2022$0.11N/AN/AN/AN/A+10.0%N/AN/ANov 14, 2022$57000
    Jun 30, 2022$0.06N/AN/AN/AN/A+500.0%N/AN/AAug 15, 2022N/A
    Mar 31, 2022$0.23N/AN/AN/AN/AN/AN/AN/AMay 16, 2022N/A
    Dec 31, 2021-$0.09N/AN/AN/AN/AN/AN/AN/AMar 31, 2022N/A
    Sep 30, 2021$0.10N/AN/AN/AN/AN/AN/AN/ANov 12, 2021N/A
    Jun 30, 2021$0.01N/AN/AN/AN/AN/AN/AN/AAug 17, 2021N/A
    Mar 31, 2021-$0.03N/AN/AN/AN/AN/AN/AN/AMay 17, 2021N/A
    Last 23 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.63, after -$1.42 the year before. It was -$0.01 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.63N/A
    Dec 31, 2024-$1.42N/A
    Dec 31, 2023-$1.07-4971.2%
    Dec 31, 2022$0.02N/A
    Dec 31, 2021-$0.01N/A

    Earnings Calls

    The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,8076

    2026Q3 Earnings Call

    Opening remarks

    Phil Carlson KCSA Managing Director Thank you, operator. Good morning, and welcome, everyone, to the Envoy Medical Third Quarter 2026 Earnings Conference Call. This is a special moment, as this is Envoy Medical's first-ever quarterly earnings call. I am joined today by members of Envoy Medical's leadership team, including Brent Lucas, Chief Executive Officer, and Robert Potashnick, Chief Accounting Officer and Vice President of Finance. Before we begin, I would like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 2000 and applicable federal securities laws. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2000. These statements, including statements regarding Envoy Medical's clinical, regulatory, and commercial plans, strategies, and estimates; the timing, results, data, and outcomes of the clinical trial; the timing of FDA submissions and potential approval; and expectations of financial or operational performance, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to the company's filings with the SEC, including our Form 10-Q for the quarter ended September 30, 2026, and our Form 10-K for the fiscal year ended December 31, 2025, for a detailed discussion of the risks and uncertainties facing Envoy Medical. With that, I would now like to turn the call over to Envoy Medical's Chief Executive Officer, Brent Lucas. Brent, please go ahead.

    Brent Lucas CEO Thank you, Phil, and good morning, everyone. Before we get into the quarter, I would like to take a few minutes to discuss who we are as a company. Many of you have supported us for years, but a growing number of investors around the world are new to Envoy Medical's story. Whether you are a long-term investor or just getting to know us, we hope you will leave today's call with an understanding of why we are so energized about Envoy Medical's future. We believe Envoy Medical is on the cusp of something transformative. With our investigational Acclaim fully implanted cochlear implant, we believe we are uniquely positioned to reshape the multibillion-dollar cochlear implant market. If our assumptions prove correct, some may one day call Envoy Medical an overnight success. The reality is that our journey to this point spans more than three decades and over $350 million of invested capital. Rome, as they say, was not built in a day. Envoy Medical was founded in 2000 with a clear goal: to create a fully implanted device that works with the natural ear.

    Frequently Asked Questions About COCH

    When is Envoy Medical's next earnings date?

    Envoy Medical's next earnings report is expected for Mar 22, 2027.

    Did COCH beat earnings estimates last quarter?

    Yes. Envoy Medical reported EPS of -$0.50 for the quarter ended Sep 30, 2026, above the -$0.70 estimate, a 28.57% surprise.

    What EPS do analysts expect from COCH next quarter?

    The consensus EPS estimate for Envoy Medical for the quarter ending Dec 31, 2026 is -$0.71 from 5 analysts, with estimates from -$0.88 to -$0.63.

    How often does COCH beat earnings estimates?

    Envoy Medical beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -2.87%.